Bevacizumab (CAS 216974-75-3) Suppliers and Product Information

Bevacizumab is a humanized IgG1 monoclonal antibody against vascular endothelial growth factor (VEGF). It inhibits tumor angiogenesis and delays disease progression. The antibody binds VEGF with high affinity (Kd = 0.5 nM) and prevents its interaction with tyrosine kinase receptors VEGFR1 and VEGFR2 on the surface of endothelial cells, thereby inhibiting cell proliferation and microvascular growth.

Bevacizumab is approved for various cancer treatments, including metastatic colorectal cancer, advanced non-small cell lung cancer, metastatic renal cell cancer, and glioblastoma multiforme. The recommended dosage is typically 5 mg/kg administered once every 2 weeks as an intravenous infusion until disease progression is detected.

Frequently Asked Questions about Bevacizumab

Q: What is the mechanism of action of Bevacizumab?

A: Bevacizumab works by binding directly to VEGF-A, blocking its interaction with endothelial cell VEGF receptors. This inhibits neovascularization and deprives cancer cells of vital nutrients and oxygen, leading to tumor growth arrest and inhibition of metastasis.

Q: What are the common side effects of Bevacizumab?

A: The most common adverse events reported in clinical trials include hypertension, diarrhea, and leucopenia. Other clinically significant adverse events occasionally reported were gastrointestinal perforations, thromboembolic events, bleeding, and proteinuria.

Q: How is Bevacizumab metabolized?

A: Bevacizumab metabolism is similar to that of endogenous IgG molecules. It primarily undergoes proteolytic catabolism throughout the body, including in endothelial cells. Its elimination does not rely primarily on the kidneys and liver. The binding of IgG to the FcRn receptor results in protection from cellular metabolism, contributing to its long terminal half-life.